LTR Pharma Ltd (LTP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LTR Pharma Ltd (LTP) has a cash flow conversion efficiency ratio of -0.070x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.39 Million ≈ $-1.69 Million USD) by net assets (AU$34.30 Million ≈ $24.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LTR Pharma Ltd - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how LTR Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read LTP liabilities breakdown for a breakdown of total debt and financial obligations.
LTR Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LTR Pharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chi Sheng Chemical
TWO:4111
|
0.013x |
|
Jorjin Technologies
TWO:4980
|
-0.015x |
|
Inv Tricahue
SN:TRICAHUE
|
0.051x |
|
UAC Global Public Company Limited
BK:UAC
|
0.070x |
|
Flagship Minerals Ltd
AU:FLG
|
-0.068x |
|
Budi Starch & Sweetener Tbk
JK:BUDI
|
0.018x |
|
PDS Biotechnology Corp
NASDAQ:PDSB
|
-0.400x |
|
Rushil Decor Limited
NSE:RUSHIL
|
0.044x |
Annual Cash Flow Conversion Efficiency for LTR Pharma Ltd (2022–2024)
The table below shows the annual cash flow conversion efficiency of LTR Pharma Ltd from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see LTP stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | AU$2.94 Million ≈ $2.08 Million |
AU$-5.09 Million ≈ $-3.60 Million |
-1.732x | -133.74% |
| 2023-06-30 | AU$2.07 Million ≈ $1.47 Million |
AU$-1.54 Million ≈ $-1.09 Million |
-0.741x | -130.74% |
| 2022-06-30 | AU$1.77 Million ≈ $1.25 Million |
AU$-568.18K ≈ $-402.02K |
-0.321x | -- |
About LTR Pharma Ltd
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australi… Read more